Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP203 in Advanced Solid Tumors
NCT05473156Phase 2Recruiting
- Sponsor
- AP Biosciences
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AP203 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (4 arms), sponsored by AP Biosciences. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events up to 90 days and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
AP203
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05473156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473156.